États-Unis · Plateformes & données · MarketBeat

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Outperform Rating at Royal Bank Of Canada

Publié par MarketBeat · États-Unis il y a 28 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Royal Bank Of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday.

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Outperform Rating at Royal Bank Of Canada

Résumé détaillé

À lire aussi

I’m 17 and will be a first-generation college student. Is law school worth being $200,000 in debt?

Afya (AFYA) Q3 2026 Earnings Call Transcript

CoreWeave continues to moderate after earnings surge, down 12%

Chicago Fed's Goolsbee says central bank 'has definitely got work to do' on inflation

Motorsport Games (MSGM) Q3 2026 Earnings Call Transcript

Goldman Sachs sees a new problem emerging for the Federal Reserve

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Outperform Rating at Royal Bank Of Canada

Résumé détaillé

Partager

À lire aussi

I’m 17 and will be a first-generation college student. Is law school worth being $200,000 in debt?

Afya (AFYA) Q3 2026 Earnings Call Transcript

CoreWeave continues to moderate after earnings surge, down 12%

Chicago Fed's Goolsbee says central bank 'has definitely got work to do' on inflation

Motorsport Games (MSGM) Q3 2026 Earnings Call Transcript

Goldman Sachs sees a new problem emerging for the Federal Reserve